Background: Patients with hematologic malignancies who undergo Haplo-HSCT (Haploidentical hematopoietic stem cell transplantation) are at a significantly higher risk for CMV (Cytomegalovirus) infection than individuals with normal immune function. This increased susceptibility to CMV is a major contributor to the morbidity and mortality seen in patients following hematopoietic stem cell transplantation.
Methods: This study involved a retrospective analysis of 113 patients who underwent allogeneic hematopoietic stem cell transplantation for malignant hematological diseases. Relevant variables were assessed through univariate analysis, and those identified in the previous literature as potential influencers of the occurrence of CMV viremia were also included in the multivariate regression analysis.
Results: Among the 113 patients with malignant hematologic diseases undergoing Haplo-HSCT, 56 cases (49.56%) were identified with CMV viremia. Initial univariate analysis highlighted patient age, graft source, and CD34+ cell dose as risk factors for CMV viremia post-transplantation. However, subsequent logistic regression analysis revealed that CD34+ cell dose stood out as an independent protective factor against CMV viremia (OR = 0.797, 95% CI: 0.644-0.987, P = 0.037).
Conclusion: Our study reveals that a higher CD34 cell dosage serves as an independent protective factor against the development of CMV viremia after Haplo-HSCT in patients with hematologic malignancies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470346 | PMC |
| http://dx.doi.org/10.62347/SOPM3064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cytomegalovirus Infections in Patients Diagnosed with Inflammatory Bowel Disease.
Infect Dis Clin Microbiol
December 2024
Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Türkiye.
Objective: The impact of cytomegalovirus (CMV) on inflammatory bowel disease (IBD) flares remains a matter of debate. This study aimed to evaluate patients with CMV infection who presented with IBD exacerbation in terms of diagnosis and treatment and investigate the importance of CMV DNA levels in colitis development.
Materials And Methods: Patients who were followed up with IBD and examined with clinical suspicion of CMV colitis at a university hospital between January 2016 and December 2021 were retrospectively scanned.
Cytokine Release Syndrome After CAR T-Cell Therapy in a 35-Year-Old Patient With Pneumonia and Cytomegalovirus Viremia.
Case Rep Med
December 2024
BMT/Hematology, Mayo Clinic, Rochester, Minnesota, USA.
The risk of cytokine release syndrome (CRS) in patients with infections prior to chimeric antigen receptor T-cell (CAR T-cell) therapy represents an important and underreported event. Patients with active infections needing prompt CAR T-cell therapy to treat aggressive hematologic malignancies remain a clinical challenge. This case describes the clinical course of a 35-year-old male patient with relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma who received axicabtagene ciloleucel.
View Article and Find Full Text PDFCytomegalovirus viremia and hepatitis B reactivation in patient with RET fusion-positive non-small cell lung cancer treated with pralsetinib.
J Oncol Pharm Pract
December 2024
Michigan Medicine, Clinical Pharmacist Specialist, Inpatient Hematology, University of Michigan, Ann Arbor, MI, USA.
Introduction: Mutated rearranged during transfection (RET) kinase is found in approximately 1-2% non-small-cell lung cancer (NSCLC) patients. These patients are typically younger, non-smokers, and have non-squamous histology. Pralsetinib is a novel RET inhibitor that showed promising efficacy and tolerability in the ARROW trial.
View Article and Find Full Text PDFCytomegalovirus reactivation (CMV-R) is a frequent complication post-allogeneic hematopoietic stem cell transplantation (allo-HSCT), associated with poor outcomes. Previous studies have demonstrated the protective effect of CMV-R against relapse after allo-HSCT for acute myeloblastic leukemia (AML). However, this impact remains unclear in acute lymphoblastic leukemia (ALL).
View Article and Find Full Text PDFMaribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: subgroup analysis of the phase 3 randomized SOLSTICE study.
J Heart Lung Transplant
November 2024
Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Background: In the phase 3 SOLSTICE study (NCT02931539), maribavir was superior to investigator-assigned therapy (IAT) for confirmed cytomegalovirus viremia clearance at study week 8 in hematopoietic cell/solid organ transplant (HCT/SOT) recipients. We report additional efficacy and safety analyses from the SOT subgroup.
Methods: Eligible solid organ transplant recipients (n=211) received maribavir 400 mg twice daily (n=142) or IAT (n=69) for 8 weeks (12 weeks' follow-up).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!